Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Ally Bridge Group
Deal Size : $68.0 million
Deal Type : Series B Financing
Epicrispr Secures $68M Series B to Advance FSHD Epigenetic Therapy Trial
Details : The financing aims to fund the clinical development of lead program, EPI-321. It is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.
Product Name : EPI-321
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 26, 2025
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Ally Bridge Group
Deal Size : $68.0 million
Deal Type : Series B Financing
Lead Product(s) : MMJ-002
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
Details : MMJ-002 is a novel cannabis-derived medication, being investigated for the treatment of chorea associated with Huntington's disease (HD).
Product Name : MMJ-002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : MMJ-002
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ADI-001
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adicet Bio Announces FDA Clearance To Evaluate ADI-001 in Inflammatory Myopathy
Details : FDA has agreed to an amendment to the company’s investigational new drug (IND) application to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome.
Product Name : ADI-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : ADI-001
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PDA-002
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Celularity Requests U.S. FDA ODD for PDA-002 in Muscular Dystrophy Treatment
Details : PDA-002 is a placenta-derived mesenchymal-like adherent stromal cell therapy, which is being evaluated for the treatment of facioscapulohumeral muscular dystrophy.
Product Name : PDA-002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : PDA-002
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARO-DUX4
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARO-DUX4 is an investigational RNAi therapeutic designed to reduce expression of the gene that encodes the human double homeobox 4 (DUX4) protein as a potential treatment for FSHD.
Product Name : ARO-DUX4
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : ARO-DUX4
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : SOLVE FSHD
Deal Size : Undisclosed
Deal Type : Financing
Details : The investment will support development of Epic’s lead program EPI-321, a novel therapeutic that is designed to correct the epigenetic alterations in the D4Z4 region of chromosome 4.
Product Name : EPI-321
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : EPI-321
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : SOLVE FSHD
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : SIG002
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SIG002 consists purified secretome free of tissue fragments and cells. SIG002 has demonstrated immunoregulatory properties relevant to address the degenerative inflammatory processes involved in osteoarthritis disease etiology.
Product Name : SIG002
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : SIG002
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Product Name : Epoladerm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm
Details : Epoladerm (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Product Name : Epoladerm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $40.0 million
Deal Type : Public Offering
Virpax ® Pharmaceuticals Announces Closing of a $ 40 Million Public Offering of Common Stock
Details : Virpax intends to use the net proceeds from the offering to fund research and development of the Epoladerm, Probudur, Envelta and AnQlar indications and other development programs in clinical trial.
Product Name : Epoladerm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $40.0 million
Deal Type : Public Offering